Epidemiology Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
Epidemiology Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA; School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Lancet Diabetes Endocrinol. 2018 Sep;6(9):725-732. doi: 10.1016/S2213-8587(18)30153-0. Epub 2018 May 31.
Vitamin D deficiency during pregnancy is associated with adverse pregnancy outcomes, although the association between preconception vitamin D concentrations and livebirth is unknown. We aimed to assess the association between preconception vitamin D and pregnancy outcomes among women with proven fecundity.
We did a secondary analysis of a prospective cohort from the block-randomised, double-blind, placebo-controlled EAGeR trial. Women aged 18-40 years with one to two previous pregnancy losses were recruited from June 15, 2007, to July 15, 2011, at four clinical sites in the USA and followed up for up to six menstrual cycles while attempting pregnancy and throughout pregnancy if they conceived. Serum 25-hydroxyvitamin D was measured at baseline (preconception) and 8 weeks of gestation. Outcomes of interest included clinical pregnancy, time to pregnancy, pregnancy loss, and livebirths. Risk ratios (RRs) and 95% CIs for livebirths, pregnancy, and pregnancy loss were estimated with weighted log-binomial regression. To assess time to pregnancy, we used discrete time Cox proportional hazards models to calculate fecundability odds ratios (FORs) with 95% CIs. EAGeR is registered with ClinicalTrials.gov, number NCT00467363.
1191 women had available data on preconception 25-hydroxyvitamin D concentrations. 555 (47%) women were classified as having sufficient concentrations (≥75 nmol/L) and 636 (53%) as having insufficient concentrations (<75 nmol/L). Women with sufficient preconception 25-hydroxyvitamin D were more likely to achieve clinical pregnancy (adjusted RR 1·10 [1·01-1·20]) and livebirth (1·15 [95% CI 1·02-1·29]) than were women with insufficient concentrations. Among women who achieved pregnancy, sufficient preconception 25-hydroxyvitamin D, but not that at 8 weeks of gestation, was associated with reduced risk of pregnancy loss (preconception RR per 25 nmol/L 0·88 [95% CI 0·77-0·99]; 8 weeks of gestation 0·98 [0·95-1·01]). No association was observed with fecundability in women with sufficient versus those with insufficient preconception 25-hydroxyvitamin D concentrations (adjusted FOR 1·13 [95% CI 0·95-1·34]).
Sufficient preconception 25-hydroxyvitamin D (≥75 nmol/L) was associated with increased likelihood of pregnancy and livebirth. Increased vitamin D concentrations before conception, but not in early pregnancy, were associated with reduced pregnancy loss.
National Institutes of Health and Doris Duke Charitable Foundation.
妊娠期间维生素 D 缺乏与不良妊娠结局有关,但孕前维生素 D 浓度与活产之间的关系尚不清楚。我们旨在评估在有生育能力的女性中,孕前维生素 D 与妊娠结局之间的关系。
我们对 EAGeR 试验的一项前瞻性队列进行了二次分析。这项随机、双盲、安慰剂对照试验于 2007 年 6 月 15 日至 2011 年 7 月 15 日在美国四个临床地点招募了年龄在 18-40 岁之间、有一到两次妊娠丢失史的女性,并对她们进行了长达六个月经周期的随访,在此期间她们尝试怀孕,一旦怀孕则进行整个孕期随访。在基线(孕前)和妊娠 8 周时测量血清 25-羟维生素 D 浓度。感兴趣的结局包括临床妊娠、妊娠时间、妊娠丢失和活产。采用加权对数二项式回归估计活产、妊娠和妊娠丢失的风险比(RR)和 95%置信区间(CI)。为了评估妊娠时间,我们使用离散时间 Cox 比例风险模型计算了有生育能力的优势比(FOR)及其 95%CI。EAGeR 在 ClinicalTrials.gov 上注册,编号为 NCT00467363。
共有 1191 名女性有可用的孕前 25-羟维生素 D 浓度数据。555 名(47%)女性被归类为具有足够的浓度(≥75nmol/L),636 名(53%)为浓度不足(<75nmol/L)。与浓度不足的女性相比,具有足够孕前 25-羟维生素 D 的女性更有可能实现临床妊娠(调整 RR 1·10[1·01-1·20])和活产(1·15[95%CI 1·02-1·29])。在实现妊娠的女性中,与妊娠 8 周时的浓度相比,足够的孕前 25-羟维生素 D 与降低妊娠丢失风险相关(每增加 25nmol/L 的 RR 0·88[95%CI 0·77-0·99];妊娠 8 周时的 RR 0·98[0·95-1·01])。在有足够的与不足的孕前 25-羟维生素 D 浓度的女性中,未观察到与生育能力的相关性(调整后的 FOR 1·13[95%CI 0·95-1·34])。
足够的孕前 25-羟维生素 D(≥75nmol/L)与增加妊娠和活产的可能性有关。受孕前维生素 D 浓度增加,但妊娠早期浓度增加与妊娠丢失减少无关。
美国国立卫生研究院和多丽丝·杜克慈善基金会。